BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27650543)

  • 1. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F; Barakat KH; Tuszynski JA
    Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM; Gillen KJ; Wallace C; Lee MT; Bakrania P; Khurana P; Coombs PJ; Stennett L; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4097-103. PubMed ID: 26318993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
    J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
    Jordheim LP; Barakat KH; Heinrich-Balard L; Matera EL; Cros-Perrial E; Bouledrak K; El Sabeh R; Perez-Pineiro R; Wishart DS; Cohen R; Tuszynski J; Dumontet C
    Mol Pharmacol; 2013 Jul; 84(1):12-24. PubMed ID: 23580445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
    De Silva IU; McHugh PJ; Clingen PH; Hartley JA
    Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
    Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
    Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.
    Bhagwat NR; Roginskaya VY; Acquafondata MB; Dhir R; Wood RD; Niedernhofer LJ
    Cancer Res; 2009 Sep; 69(17):6831-8. PubMed ID: 19723666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
    Li W; Melton DW
    Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM; Melton DW
    Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
    Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
    Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling Novel ERCC1-XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design.
    Manguinhas R; Serra PA; Soares RB; Rosell R; Gil N; Oliveira NG; Guedes RC
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM; Wallace C; Gillen KJ; Bakrania P; Khurana P; Coombs PJ; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4104-8. PubMed ID: 26321360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.